Investing.com - Financial Markets Worldwide

Sun Pharmaceutical Industries Ltd. (SUN)

NSE
Symbol
Exchange
Currency
SUN·NSE·INR
SUNc1:NS·NSE·INR
SUNc2:NS·NSE·INR
SUN·BSE·INR
Currency in INR
1,692.00
+9.50(+0.56%)
Closed·

SUN Financial Summary

Key Ratios

P/E Ratio37.14
Price/Book5.66
Debt / Equity3.26%
Return on Equity15.71%
Dividend Yield0.95%
EBITDA149.68B
Fair ValueUnlock
Fair Value UpsideUnlock

Statements Highlights

Period Ending:
2016
31/03
2017
31/03
2018
31/03
2019
31/03
2020
31/03
2021
31/03
2022
31/03
2023
31/03
2024
31/03
2025
31/03
Income Statement
Total Revenues
aa.aaaa.aaaa.aaaa.aaaa.aa334,981.4386,544.9438,856.8484,968.5525,784.4
Gross Profit
aa.aaaa.aaaa.aaaa.aaaa.aa242,796.2277,783.5325,670.1370,546.7410,199.9
Operating Income
aa.aaaa.aaaa.aaaa.aaaa.aa64,276.281,560.493,057.5105,201.5126,054.8
Net Income
aa.aaaa.aaaa.aaaa.aaaa.aa29,038.232,727.384,735.895,763.8109,290.4
Balance Sheet
Total Assets
aa.aaaa.aaaa.aaaa.aaaa.aa676,667.3698,077.7807,435.9854,996.5921,005.8
Total Current Liabilities
aa.aaaa.aaaa.aaaa.aaaa.aa161,456.3172,084.5199,070169,844181,942.1
Total Equity
aa.aaaa.aaaa.aaaa.aaaa.aa494,798.3510,661.1593,154.7671,259.4724,859.5
Cash Flow
Levered Free Cash Flow
aa.aaaa.aaaa.aaaa.aaaa.aa84,288.5975,692.717,911.0475,827.582,397.35
Cash from Operations
aa.aaaa.aaaa.aaaa.aaaa.aa61,703.789,845.449,593.3121,349.8140,720.9
Cash from Investing
aa.aaaa.aaaa.aaaa.aaaa.aa5,362.2-57,247.4-79,436.8-6,902-53,061.6
Cash from Financing
aa.aaaa.aaaa.aaaa.aaaa.aa-59,804.8-51,934.623,760.7-67,101.6-79,058.2
Net Change in Cash
aa.aaaa.aaaa.aaaa.aaaa.aa5,964.2-17,647.81,154.846,619.29,831.2
* In Millions of INR (except for per share items)

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 45.55%
Dividend Yield
0.95%
Industry Median 0.74%
Annualised payout
16.00
Paid unevenly
5-Years Growth
+31.95%
Growth Streak
Unlock

Analyst Ratings

28 Buy
4 Hold
4 Sell
Ratings:
36 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 1,974.49
(+16.70% Upside)

Earnings

Latest Release
May 22, 2025
EPS / Forecast
10.65 / 10.96
Revenue / Forecast
129.59B / 134.28B
EPS Revisions
a
a
Unlock
Last 90 days

FAQ

What were Sun Pharma's earnings for the latest quarter?

The Sun Pharma EPS (TTM) is 45.55. Sun Pharma reported sales of 129,588.40, net income of 21,498.80, and EPS of 10.65 for the latest quarter.

What was Sun Pharma's net income for the latest quarter?

Sun Pharma's net income for the latest quarter was 21,498.80.

How did Sun Pharma's performance compare year-over-year in the latest quarter?

The company's revenue moved from 136,754.60 in the previous quarter to 129,588.40 in the latest quarter, and net income moved from 29,033.80 to 21,498.80 compared to the previous quarter.

What is Sun Pharma's net profit margin on a TTM basis?

Sun Pharma's trailing twelve months (TTM) net profit margin is 20.79%.

How does Sun Pharma's debt to equity ratio compare to industry standards?

Sun Pharma's total debt-to-equity ratio is 3.26%.

What is Sun Pharma's return on investment on a TTM basis?

Sun Pharma's trailing twelve months (TTM) return on investment (ROI) is 15.71%.

What were Sun Pharma's total assets and liabilities in the latest quarter?

As of the latest quarter, Sun Pharma reported total assets of 921,005.80 million and total liabilities of 181,942.10 million.

How has Sun Pharma's total revenue grown this year?

Sun Pharma's total revenue was 136,754.60 in the previous quarter and 129,588.40 in the latest quarter.

What is Sun Pharma's gross margin on a TTM basis?

Sun Pharma's trailing twelve months (TTM) gross margin is 78.02%.

What was Sun Pharma's revenue per share for the latest quarter?

Sun Pharma's revenue per share for the latest quarter was 295.58.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.